Peer Reviewed

Proteomics in Practice: Potential Consequences of Long-term Anti-VEGF Therapy


Proteomics in Practice: Potential Consequences of Long-term Anti-VEGF Therapy

K. V. Chalam, MD, PhD • Vikram S. Brar, MD

Reactive oxygen species (ROS) are generated in normal metabolic processes, and the imbalance between their production and detoxification generates oxidative stress. In the setting of increased ROS, cell membranes, nucleic acids and proteins are vulnerable to chemical modification and promote cell death via apoptosis. Oxidative stress has been implicated in the pathogenesis of many ocular diseases, including glaucoma,1 diabetic retinopathy2 and AMD,3 in which it has been linked to increased expression of vascular endothelial growth factor. VEGF has been implicated in a variety of retinal vascular conditions,4-10 and treatment with anti-VEGF agents has emerged as the standard of care in the management of these diseases.11-21

However, VEGF has also been described as a neuroprotectant,22-25 particularly against oxidative stress in the central nervous system26-30 and the retina.31-32 Thus, total VEGF blockade with anti-VEGF agents may have unintended negative effects.33 We summarize the role of oxidative stress in selected, irreversibly blinding ocular diseases, highlight the role of VEGF in neuroprotection and describe the potential consequences of anti-VEGF therapy on retinal ganglion cells.31


Oxidative stress has also been implicated in glaucoma,1 another significant cause of irreversible blindness.34 Elevated oxidative markers have been demonstrated in the aqueous humor of glaucomatous eyes,35-36 and treatment with topical dorzolamide has been shown to decrease them.36 Retinal ganglion cells are vulnerable to oxidative stress via their high metabolic demand and exposure to light.37-38 Subsequent damage to cell membranes and nucleic acids, both mitochondrial and nuclear, result in cell death, classically through apoptosis.39-40

Melatonin, a known antioxidant, exhibits neuroprotection, independent of elevated intraocular pressure, by positively influencing oxidative markers and increasing superoxide dismutase and glutathione levels, while decreasing thiobarbituric acid reactive substances (a measure of lipid peroxidation).41 Several other antioxidant compounds are being evaluated in the treatment of glaucoma.42


In the United States, diabetic retinopathy is the main cause of permanent vision loss in the working population.43 Oxidative stress plays a central role in the development of diabetic retinopathy, in which hyperglycemia induces superoxide production by the mitochondria as the sentinel event.44 In the polyol pathway, hyperglycemia results in the conversion of glucose to sorbitol by aldose reductase.45-46 This pathway consumes NADPH, a required cofactor in the regeneration of glutathione. Therefore, deprivation of NADPH diminishes defense against oxidative stress.47

Reactive oxygen species also lead to reduced activity of glyceraldehyde-3 phosphate dehydrogenase, which regulates several pathways implicated in oxidative stress, one of which is the protein kinase C (PKC) pathway.44 PKC activation results in the production of proinflammatory advanced glycation end-products.48

Further, PKC has also been shown to have effects on vascular permeability.2 This and other pathological effects in the retina culminated in a multicenter prospective randomized clinical trial, which demonstrated a positive role for the PKC inhibitor ruboxistaurin on vision loss in non-proliferative diabetic retinopathy.49


Age-related macular degeneration is a major cause of blindness in the world.50 There is increasing evidence that pathogenic oxidative mechanisms contribute to the progression of AMD.3,51-54 Due to the retina's high metabolic activity, its concentration of polyunsaturated fatty acids and its continuous exposure to light, it is highly susceptible to oxidative stress and the subsequent generation of ROS.3,54

More specifically, phagocytosis of outer segments by the RPE results in the generation of the superoxide anion, hydroxyl radicals and hydrogen peroxide.55 The subsequent oxidative stress results in the induction of apoptosis in RPE cells.32,53 Further, oxidative stress has been shown to induce VEGF-A and VEGF-C secretion in RPE cells, leading to the development of choroidal neovascularization.56 However, VEGF-A also plays a protective role against oxidative stress–induced apoptosis.32


Vascular endothelial growth factor acts primarily as an angiogenic, as well as a vasopermeable, agent.57-58 The VEGF family includes VEGF-A-E and placental growth factor, with VEGF-C primarily involved in lymphangiogenesis.59 In addition to its effects on endothelial cells, VEGF plays an essential role in the development and maturation of neural tissue, such as in the retina.27 Developmentally, astrocytes in the retinal ganglion cell layer, cells of the inner nuclear layer, Müller cells and RPE cells all express VEGF.60-61 Physiologically, in the mature retina, VEGF is expressed in the absence of active neovascularization and maintains the homeostasis of adult retinal neurons.33

Specifically, VEGF-A has been implicated in retinal vascular disease, in which increased VEGF expression was due to retinal ischemia.62 Increased VEGF expression occurs in many vascular conditions of the retina, including AMD and diabetic retinopathy.4-10

In different cell types, VEGF expression is initiated under the influence of oxidative stress, which may have both pathologic and protective effects on surrounding cells. Moreover, increased VEGF expression promotes survival in aortic endothelial cells exposed to cytotoxic agents, including hydrogen peroxide.63 In the retina, such induction of VEGF results in the development of neovascular AMD56 and conversely protects against oxidative cell death in an autocrine fashion in RPE cells.32


VEGF has also been shown to be neuroprotective in many models of central nervous system injury. Early reports described VEGF protection following ischemic insults in the rat brain.22 VEGF also protected spinal cord neurons in vitro from glutamate-induced excitotoxicity.23 With regard to the eye, VEGF-A reduced apoptosis in retinal neurons following ischemic injury24 and delayed degeneration in retinal ganglion cells following axotomy.25

Oxidative stress related to mutations in superoxide dismutase (SOD) contributes to the pathogenesis of amytrophic lateral sclerosis (ALS), a progressive neurodegenerative disorder, in which VEGF has also been implicated.64 A more severe form of the disease was encountered in a VEGF-deficient mouse model of ALS, compared to the wild type.26 In SOD-1 mutant mice, enhanced VEGF expression decreased oxidative stress and improved neuronal cell survival.27 This result led to attempts to reduce motor neuron degeneration with an intraventricular injection of VEGF in a rat model of ALS.28 Further, both intraperitoneal29 and intramuscular30 injections of VEGF increased survival in mouse models. VEGF has demonstrated promise in the management of oxidative stress–related neurodegenerative disease, although its exact mechanism and role in the future is being evaluated.64


Several different pathways have been described to explain the cytoprotective effect mediated by VEGF against oxidative stress. VEGF has been shown to induce mitochondrial SOD, a major enzyme in the defense against oxidative stress.65 Subsequently, enhanced VEGF expression was shown to protect neuronal cells from oxidative stress induced by 3-nitropropionic acid (3-NP), an inhibitor of succinic acid dehydrogenase. This result was accomplished through induction of SOD, and treatment with anti-VEGF antibodies abrogated this effect.66

Similarly, VEGF was shown to protect against ROS through induction of heme oxygenase-1 (HO-1), an oxidative enzyme, in an animal model of hyperoxic acute lung injury.67 In another study, involving endothelial cell response to cytotoxic levels of hydrogen peroxide, VEGF expression was associated with increased cell survival, which was coupled with a rise in NF-κB.68 In a cell culture model, VEGF was shown to protect motor neurons from hydrogen peroxide–mediated oxidative stress through the antiapoptotic phosphatidylinositol 3-kinase (PI3-K)/Akt pathway.69 This mechanism was confirmed in human RPE cells in culture, in which treatment with VEGF-A protected RPE cells from hydrogen peroxide–induced apoptosis.32 In summary, VEGF appears to protect against oxidative stress through induction of antioxidant agents (SOD and HO-170-71) and pathways associated with cell survival (NF-κB72 and PI3-K/Akt73).


Numerous anti-VEGF agents have been introduced for clinical use.74-78 However, due to lower cost, efficacy, and expanding clinical applications, bevacizumab has emerged as the most commonly employed agent. Intravitreal injections of bevacizumab, a humanized monoclonal antibody, are widely used in the treatment of neovascular AMD,20-21 as well as in other vascular diseases of the posterior segment.13-19

With regard to bevacizumab, numerous reports have failed to demonstrate any toxicity of this agent.79-83 However, in lieu of VEGF-mediated neuroprotection, anti-VEGF therapy may have negative effects on cells in the retina. Animal studies have shown that systemic neutralization of VEGF with soluble VEGF receptors resulted in reduced thickness of the inner and outer nuclear layer in the adult mouse retina.33 Thus, repeated treatment with anti-VEGF agents may negate the physiologic function and neutralize VEGF mediated neuroprotection.


We evaluated the protective role of VEGF against oxidative stress in differentiated retinal ganglion cells84 and the effect of anti-VEGF therapy on the process. Oxidative stress was induced using hydrogen peroxide to simulate conditions faced by retinal ganglion cells in various ocular diseases. Co-treatment with VEGF165 protected cells from hydrogen peroxide–mediated cell toxicity, and this effect was neutralized by bevacizumab.

The glutathione reductase inhibitor buthionine sulfoxime (BSO) also eliminated VEGF-mediated cytoprotection. This result is supported by the fact that VEGF induces SOD,66 one product of which, hydrogen peroxide, is converted to water and oxygen by glutathione peroxidase through oxidation of glutathione. BSO treatment depletes the store of reduced glutathione and reduces the ability of the cell to respond to oxidative stress. This protective effect is especially relevant in the setting of combination therapy with anti-VEGF agents and of brachytherapy in the management of CNV membranes, in which radiation-mediated induction of ROS induces choroidal endothelial cell death.85-86


Oxidative stress–mediated toxicity is common in several sight-threatening ocular conditions, in which VEGF plays both a pathologic and protective role. Anti-VEGF therapy can negate this role and enhance oxidative stress and, thus, should be administered with caution, as long-term intravitreal usage of bevacizumab may have collateral effects on retinal cells, although these results have been borne out in animal models only. RP


1. Kumar DM, Agarwal N. Oxidative stress in glaucoma: a burden of evidence. J Glaucoma. 2007;16:334-343.
2. Madsen-Bouterse SA, Kowluru RA. Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Rev Endocr Metab Disord. 2008;9:315-327.
3. Beatty S, Koh H, Phil M, et al. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000;45:115-134.
4. Ferrara N, Mass RD, Campa C, et al. Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med. 2007;58:491-504.
5. Duh EJ, Yang HS, Haller JA, et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis. Am J Ophthalmol. 2004;137:668-674.
6. Chan WM, Lai TY, Chan KP, et al. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived growth factor levels following intravitreal bevacziuamb injections for choroidal neovascularization secondary to Age-Related Macular Degeneration or pathologic myopia. Retina. 2008 Aug 25. [Epub ahead of print]
7. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
8. Grover S, Gupta S, Sharma R, et al. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. Br J Ophthalmol. 2009;93:273-274.
9. Sharma RK, Rogojina AT, Chalam KV. Bevacizumab therapy normalizes the pathological intraocular environment beyond neutralizing VEGF. Mol Vis. 2010;16:2175-2184.
10. Campochiaro PA, Choy DF, Do DV, et al. Monitoring ocular drug therapy by analysis of aqueous samples. Ophthalmology. 2009;116:2158-2164. Epub 2009 Aug 22.
11. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
12. Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–1444.
13. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology. 2007;114:743-750.
14. Kook D, Wolf A, Kreutzer T, et al. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina. 2008;28:1053-1060.
15. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina. 2007;27:141-149.
16. Charbel Issa P, Finger RP, Holz FG, et al. Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Br J Ophthalmol. 2008;92:941-945.
17. Arevalo JF, Garcia-Amaris RA, Roca JA, et al. Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: pilot study of the Pan-American Collaborative Retina Study Group. J Cataract Refract Surg. 2007;33:2098-2105.
18. Mirshahi A, Namavari A, Djalilian A, et al. Intravitreal bevacizumab (Avastin) for the treatment of cystoid macular edema in Behçet disease. Ocul Immunol Inflamm. 2009;17:59-64.
19. Chalam KV, Gupta SK, Grover S, et al. Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma. Eur J Ophthalmol. 2008;18:255-262.
20. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331-335.
21. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-372.
22. Sun Y, Jin K, Xie L, et al. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest. 2003;111:1843-18510.
23. Tolosa L, Mir M, Asensio VJ, et al. Vascular endothelial growth factor protects spinal cord motoneurons against glutamate-induced excitotoxicity via phosphatidylinositol 3-kinase. J Neurochem. 2008;105:1080-1090. Epub 2007 Dec 25.
24. Nishijima K, Ng YS, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007;171:53-67.
25. Kilic U, Kilic E, Järve A, et al. Human vascular endothelial growth factor protects axotomized retinal ganglion cell in vivo by activating ERK-1/2 and Akt pathways. J Neurosci. 2006;26:12439-12446.
26. Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet. 2003;34:383-394.
27. Wang Y, Mao XO, Xie L, et al. Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice. J Neurosci. 2007;27:304-307.
28. Storkebaum E, Lambrechts D, Dewerchin M, et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci. 2005;8:85-92.
29. Zheng C, Nennesmo I, Fadeel B, et al. Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS. Ann Neurol. 2004;56:564-567.
30. Azzouz M, Ralph GS, Storkebaum E, et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature. 2004;429:413-417.
31. Brar VS, Sharma RK, Murthy RK, et al. Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells. Mol Vis. 2010;16:1848-1853.
32. Byeon SH, Lee SC, Choi SH, et al. Vascular endothelial growth factor as an autocrine survival factor for retinal pigment epithelial cells under oxidative stress via the VEGF-R2/PI3K/Akt. Invest Ophthalmol Vis Sci. 2010;51:1190-1197. Epub 2009 Oct 15.
33. Saint-Geniez M, Maharaj ASR, Walshe TE, et al. Endogenous VEGF Is Required for Visual Function: Evidence for a Survival Role on Müller Cells and Photoreceptors. PLoS ONE. 2008;3:e3554.
34. Cedrone C, Mancino R, Cerulli A, et al. Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects. Prog Brain Res. 2008;173:3-14.
35. Ferreira SM, Lerner SF, Brunzini R, et al. Oxidative stress markers in aqueous humor of glaucoma patients. Am J Ophthalmol. 2004;137:62-69.
36. Zanon-Moreno V, Garcia-Medina JJ, Gallego-Pinazo R, et al. Antioxidant status modifications by topical administration of dorzolamide in primary open-angle glaucoma. Eur J Ophthalmol. 2009;19:565-571.
37. Organisciak DT, Darrow RM, Barsalou L, et al. Light history and age-related changes in retinal light damage. Invest Ophthalmol Vis Sci. 1998;39:1107-1116.
38. Balaiya S, Murthy RK, Brar VS, et al. Evaluation of ultraviolet light toxicity on cultured retinal pigment epithelial and retinal ganglion cells. Clin Ophthalmol. 2010;4:33-39.
39. Maher P, Hanneken A. The molecular basis of oxidative stress-induced cell death in an immortalized retinal ganglion cell line. Invest Ophthalmol Vis Sci. 2005;46:749-757.
40. Baltmr A, Duggan J, Nizari S, et al. Neuroprotection in glaucoma - Is there a future role? Exp Eye Res. 2010;91:554-566. Epub 2010 Aug 26.
41. Belforte NA, Moreno MC, de Zavalía N, et al. Melatonin: a novel neuroprotectant for the treatment of glaucoma. J Pineal Res. 2010;48:353-364. Epub 2010 Mar 16.
42. Mozaffarieh M, Grieshaber MC, Orgül S, et al. The potential value of natural antioxidative treatment in glaucoma. Surv Ophthalmol. 2008;53:479-505.
43. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007;14:179-183.
44. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058-1070.
45. Gabbay KH. Hyperglycemia, polyol metabolism, and complications of diabetes mellitus. Annu Rev Med. 1975;26:521-536.
46. Dagher Z, Park YS, Asnaghi V, et al. Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes. 2004;53:2404-2411.
47. Bravi MC, Pietrangeli P, Laurenti O, et al. Polyol pathway activation and glutathione redox status in non-insulin-dependent diabetic patients. Metabolism. 1997;46:1194-1198.
48. Xu Y, Wang S, Feng L, Zhu Q, Xiang P, He B. Blockade of PKC-beta protects HUVEC from advanced glycation end products induced inflammation. Int Immunopharmacol. 2010;10:1552-1559. Epub 2010 Sep 27.
49. PKC-DRS2 Group, Aiello LP, Davis MD, Girach A, et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology. 2006;113:2221-2230. Epub 2006 Sep 20.
50. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82:844-851. Epub 2004 Dec 14.
51. Jin GF, Hurst JS, Godley BF. Hydrogen peroxide stimulates apoptosis in cultured human retinal pigment epithelial cells. Curr Eye Res. 2001;22:165-173.
52. Rozanowska M, Jarvis-Evans J, Korytowski W, et al. Blue light-induced reactivity of retinal age pigment. In vitro generation of oxygen-reactive species. J Biol Chem. 1995;270:18825–18830.
53. Winkler BS, Boulton ME, Gottsch JD, et al. Oxidative damage and age-related macular degeneration. Mol Vis. 1999;5:32.
54. Khandhadia S, Lotery A. Oxidation and age-related macular degeneration: insights from molecular biology. Expert Rev Mol Med. 2010;12:e34.
55. Tate DJ, Miceli MV, Newsome DA. Phagocytosis and H2O2 induce catalase and metallothionein gene expression in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1995;36:1271-1279.
56. Kannan R, Zhang N, Sreekumar PG, et al. Stimulation of apical and basolateral VEGF-A and VEGF-C secretion by oxidative stress in polarized retinal pigment epithelial cells. Mol Vis. 2006;12:1649-1659.
57. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Comm. 1989;161:851-859.
58. Keck PJ, Hauser SD, Krivi G, et al. Vascular Permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989;246:1309-1312.
59. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26:859-870.
60. Darland DC, Massingham LJ, Smith SR, et al. Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev Biol. 2003;264:275-288.
61. Saint-Geniez, M, Maldonado AE, D'Amore PA. VEGF expression and receptor activation in the choroid during development and in the adult. Invest Ophthalmol Vis Sci. 2006;47:3135-3142.
62. Shima DT, Adamis AP, Ferrara N, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med. 1995;1:182-193.
63. Castilla MA, Caramelo C, Gazapo RM, et al. Role of vascular endothelial growth factor (VEGF) in endothelial cell protection against cytotoxic agents. Life Sci. 2000;67:1003-1013.
64. Sathasivam S. VEGF and ALS. Neurosci Res. 2008;62:71-77. Epub 2008 Jul 9.
65. Abid MR, Schoots IG, Spokes KC, et al. Vascular endothelial growth factor-mediated induction of manganese superoxide dismutase occurs through redox-dependent regulation of forkhead and IkappaB/NF-kappaB. J Biol Chem. 2004;279:44030-44038. Epub 2004 Aug 11.
66. Madhavan L, Ourednik V, Ourednik J. Neural stem/progenitor cells initiate the formation of cellular networks that provide neuroprotection by growth factor-modulated antioxidant expression. Stem Cells. 2008;26:254-265.
67. Siner JM, Jiang G, Cohen ZI, et al. VEGF-induced heme oxygenase-1 confers cytoprotection from lethal hyperoxia in vivo. FASEB J. 2007;21:1422-1432.
68. González-Pacheco FR, Deudero JJ, Castellanos MC, et al. Mechanisms of endothelial response to oxidative aggression: protective role of autologous VEGF and induction of VEGFR2 by H2O2. Am J Physiol Heart Circ Physiol. 2006;291:H1395-1401.
69. Li B, Xu W, Luo C, et al. VEGF-induced activation of the PI3-K/Akt pathway reduces mutant SOD1-mediated motor neuron cell death. Brain Res Mol Brain Res. 2003;111:155-164.
70. Takahashi T, Shimizu H, Morimatsu H, et al. Heme oxygenase-1: a fundamental guardian against oxidative tissue injuries in acute inflammation. Mini Rev Med Chem. 2007;7:745-753.
71. Morse D, Lin L, Choi AM, et al. Heme oxygenase-1, a critical arbitrator of cell death pathways in lung injury and disease. Free Radic Biol Med. 2009;47:1-12. Epub 2009 Apr 9.
72. Wooten MW. Function for NF-κB in neuronal survival: regulation by atypical protein kinase C. J Neurosci Res. 1999;58:607-611.
73. Kim AH, Khursigara G, Sun X, et al. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol. 2001;21:893-901.
74. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
75. Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
76. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431.
77. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331-335.
78. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-372.
79. Xu W, Wang H, Wang F, et al. Testing toxicity of multiple intravitreal injections of bevacizumab in rabbit eyes. Can J Ophthalmol. 2010;45:386-392.
80. Pedersen KB, Møller F, Sjølie AK, et al. Electrophysiological assessment of retinal function during 6 months of bevacizumab treatment in neovascular age-related macular degeneration. Retina. 2010;30:1025-1033.
81. Thaler S, Fiedorowicz M, Choragiewicz TJ, et al. Toxicity testing of the VEGF inhibitors bevacizumab, ranibizumab and pegaptanib in rats both with and without prior retinal ganglion cell damage. Acta Ophthalmol. 2010;88:e170-6. Epub 2010 May 14.
82. Guo B, Wang Y, Hui Y, et al. Effects of anti-VEGF agents on rat retinal Müller glial cells. Mol Vis. 2010;16:793-799.
83. Brar VS, Sharma RK, Murthy RK, et al. Evaluation of differential toxicity of varying doses of bevacizumab on retinal ganglion cells, retinal pigment epithelial cells, and vascular endothelial growth factor-enriched choroidal endothelial cells. J Ocul Pharmacol Ther. 2009;25:507-511.
84. Frassetto LJ, Schlieve CR, Lieven CJ, et al. Kinase-dependent differentiation of a retinal ganglion cell precursor. Invest Ophthalmol Vis Sci. 2006;47:427-438.
85. Robbins ME, Zhao W. Chronic oxidative stress and radiation-induced late normal tissue injury: a review. Int J Radiat Biol. 2004;80:251-259. Review.
86. Avila MP, Farah ME, Santos A et al. Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration. Br J Ophthalmol. 2009;93:305-309. Epub 2008 Nov 19.

K. V. Chalam, MD, PhD, and Vikram S. Brar, MD, are on the faculty of the Department of Ophthalmology at the University of Florida College of Medicine in Jacksonville. Neither author reports any financial interest in any product mentioned in this article. Dr. Chalam can be reached via e-mail at